SCHEMBL3751209

SCHEMBL3751209

CS(=O)(=O)c1ccc(CNC(=O)C2c3cc(Cl)ccc3C(=O)N2C(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.52
P2RX7 Q99572 3/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KCNH2 Q12809 2/20 0.40
SCN9A Q15858 2/20 0.40
ALDH1A1 P00352 1/20 0.39
TUBB P07437 1/20 0.39
CCR5 P51681 1/20 0.39
BRS3 P32247 1/20 0.39
ELANE P08246 1/20 0.38
MAPK8 P45983 1/20 0.38
SCN5A Q14524 1/20 0.38
DRD2 P14416 1/20 0.38
RORC P51449 1/20 0.38
CCR1 P32246 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3752066 0.92 KCNA5 (0.64) KCNA5P2RX7CYP3A4TSHRHSD17B10
SCHEMBL3755647 0.90 KCNA5 (0.61) KCNA5P2RX7TSHRKCNH2SCN9A
SCHEMBL3748956 0.89 KCNA5 (0.66) KCNA5CYP3A4TSHRHSD17B10CYP2C9
SCHEMBL3756768 0.89 P2RX7 (0.53) KCNA5P2RX7
SCHEMBL3756446 0.87 P2RX7 (0.45) KCNA5P2RX7ELANE
SCHEMBL3750444 0.83 KCNA5 (0.48) KCNA5P2RX7TSHRKCNH2ALDH1A1
SCHEMBL3754228 0.82 KCNA5 (0.77) KCNA5P2RX7KCNH2SCN9AALDH1A1
SCHEMBL3745315 0.82 KCNA5 (0.77) KCNA5P2RX7KCNH2SCN9AALDH1A1
SCHEMBL3756535 0.81 KCNA5 (0.64) KCNA5P2RX7CYP3A4TSHRHSD17B10
SCHEMBL3750488 0.81 KCNA5 (0.53) KCNA5P2RX7CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885P2RX7 1839/4885CYP3A4 74/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885P2RX7 1138/4885CYP3A4 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.